Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA.

JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741.


Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.

Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS.

Cancer. 2016 Mar 1;122(5):766-72. doi: 10.1002/cncr.29812.


Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG.

Cancer. 2015 Feb 1;121(3):448-56. doi: 10.1002/cncr.29042.


Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.

Yeung SF, Tong JH, Law PP, Chung LY, Lung RW, Tong CY, Chow C, Chan AW, Wan IY, Mok TS, To KF.

J Thorac Oncol. 2015 Sep;10(9):1292-300. doi: 10.1097/JTO.0000000000000620.


Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.

Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA.

Clin Cancer Res. 2015 Aug 15;21(16):3631-9. doi: 10.1158/1078-0432.CCR-14-2683.


Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.

Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L, Sun Y, Chen H.

Lung Cancer. 2013 Jan;79(1):8-13. doi: 10.1016/j.lungcan.2012.09.018.


Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB.

Lung Cancer. 2015 Dec;90(3):369-74. doi: 10.1016/j.lungcan.2015.10.028.


Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.

Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators..

J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516.


Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.

Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, Maniwa T, Takahashi T, Endo M, Nakajima T, Ohde Y, Yamamoto N.

Cancer. 2014 May 15;120(10):1471-81. doi: 10.1002/cncr.28604.


Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G.

J Clin Oncol. 2015 Mar 20;33(9):1000-7. doi: 10.1200/JCO.2014.58.2007.


Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.

Hsu KH, Ho CC, Hsia TC, Tseng JS, Su KY, Wu MF, Chiu KL, Yang TY, Chen KC, Ooi H, Wu TC, Chen HJ, Chen HY, Chang CS, Hsu CP, Hsia JY, Chuang CY, Lin CH, Chen JJ, Chen KY, Liao WY, Shih JY, Yu SL, Yu CJ, Yang PC, Chang GC.

PLoS One. 2015 Mar 19;10(3):e0120852. doi: 10.1371/journal.pone.0120852.


Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.

Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H.

J Clin Oncol. 2010 Oct 20;28(30):4616-20. doi: 10.1200/JCO.2010.29.6038.


Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W, Chen H.

Clin Cancer Res. 2012 Apr 1;18(7):1947-53. doi: 10.1158/1078-0432.CCR-11-2511.


[Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].

Fournier C, Greillier L, Fina F, Secq V, Nanni-Metellus I, Loundou A, Garcia S, Ouafik L, Tomasini P, Barlesi F.

Rev Mal Respir. 2016 Mar 23. pii: S0761-8425(16)00052-8. doi: 10.1016/j.rmr.2015.12.009. French.


Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.

Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris MG.

Mol Cancer Ther. 2012 Feb;11(2):485-91. doi: 10.1158/1535-7163.MCT-11-0692.


Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.

Wen YS, Cai L, Zhang XW, Zhu JF, Zhang ZC, Shao JY, Zhang LJ.

Medicine (Baltimore). 2014 Dec;93(29):e296. doi: 10.1097/MD.0000000000000296.


Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ.

Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246.


Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.

Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, Chen H, Ji H.

PLoS One. 2011;6(11):e28204. doi: 10.1371/journal.pone.0028204.


Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M.

Clin Cancer Res. 2012 Sep 15;18(18):4910-8. doi: 10.1158/1078-0432.CCR-12-0912.


Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.

Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, Ye T, Hu H, Luo X, Li H, Zhang Y, Zhang J, Zhou X, Shen L, Pao W, Sun Y, Chen H.

J Thorac Oncol. 2014 Jun;9(6):760-8. doi: 10.1097/JTO.0b013e3182a406d1.

Items per page

Supplemental Content

Support Center